NEW STRATEGIES AND APPLICATIONS FOR DRUGS TARGETING EGFR AND C-MET

Aims & Scope:
The growth factor receptors EGFR and c-Met are widely expressed on cancer cells and are implicated in the development and progression of many tumor types through multiple effects on cell cycle progression, apoptosis, and invasion, using a highly overlapping repertoire of signalling adaptors and downstream pathways. However, EGFR and Met inhibitors have been approved only for a limited number of malignancies, and further studies to evaluate novel applications, as well as identify biomarkers to guide these treatments are warranted. Similarly, new drug combinations might represent a major strategy to overcome the reasons of their failures, such as inherent or acquired resistance, in different tumors. Therefore, this special issue will provide the readers working in basic biomedical sciences as well as clinicians a comprehensive overview of novel compounds interacting with EGFR and c-Met, with the aim of clarifying their development, pharmacology, resistance factors, and new therapeutic strategies against major solid tumors.

Key words: 
EGFR and c-Met; cancer; pharmacokinetics; pharmacodynamics; pharmacogenetics; drug combinations

Subtopics:
Clinical pharmacology of EGFR/c-Met inhibitors
Epidermal Growth Factor Receptor targeting in Non-Small Cell Lung Cancer: Revisiting different strategies against the same target
The role of c-Met in in Non-Small Cell Lung Cancer resistant to EGFR inhibitors
Targeting c-Met/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
EGFR as a potential target for the treatment of pancreatic cancer: a therapeutic dilemma
Novel drug combinations of EGFR and c-Met inhibitors with targeted and chemotherapeutic agents
New potential biomarkers for EGFR and c-Met inhibitors

Schedule:
Manuscript submission deadline: July 2014
Peer Review Due: August 2014
Revision Due: September 2014
Notification of acceptance by the Guest Editor: September 2014
Final manuscripts due: October 2014